These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

75 related items for PubMed ID: 11324452

  • 1. Vulnerable substrate and multiple ion channel disorder in a diseased heart will be new targets for antiarrhythmic therapy.
    Dai DZ.
    Acta Pharmacol Sin; 2000 Apr; 21(4):289-95. PubMed ID: 11324452
    [Abstract] [Full Text] [Related]

  • 2. Two patterns of ion channelopathy in the myocardium: perspectives for development of anti-arrhythmic agents.
    Dai DZ.
    Curr Opin Investig Drugs; 2005 Mar; 6(3):289-97. PubMed ID: 15816506
    [Abstract] [Full Text] [Related]

  • 3. [Failure of antiarrhythmia agents and understanding the phenomenon of proarrhythmia].
    Semrád B.
    Vnitr Lek; 2003 Sep; 49(9):700-6. PubMed ID: 14584417
    [Abstract] [Full Text] [Related]

  • 4. [HERG K+ channel, the target of anti-arrhythmias drugs].
    Guan FY, Yang SJ.
    Yao Xue Xue Bao; 2007 Jul; 42(7):687-91. PubMed ID: 17882949
    [Abstract] [Full Text] [Related]

  • 5. [Ventricular arrhythmias. A potential risk associated with the use of non-cardiovascular drugs prolonging the QT interval].
    Calderone V, Cavero I.
    Minerva Med; 2002 Jun; 93(3):181-97. PubMed ID: 12094149
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Induced ion currents and the endothelin pathway as targets for anti-arrhythmic agents.
    Dai DZ, Dai Y.
    Curr Opin Investig Drugs; 2008 Sep; 9(9):1001-8. PubMed ID: 18729007
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. CPU86017: a novel Class III antiarrhythmic agent with multiple actions at ion channels.
    Dai DZ.
    Cardiovasc Drug Rev; 2006 Sep; 24(2):101-15. PubMed ID: 16961724
    [Abstract] [Full Text] [Related]

  • 13. Ischemic modulation of vulnerable period and the effects of pharmacological treatment of ischemia-induced arrhythmias: a simulation study.
    Cimponeriu A, Starmer CF, Bezerianos A.
    IEEE Trans Biomed Eng; 2003 Feb; 50(2):168-77. PubMed ID: 12665030
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. The Long QT Syndrome.
    Vohra J.
    Heart Lung Circ; 2007 Feb; 16 Suppl 3():S5-12. PubMed ID: 17627884
    [Abstract] [Full Text] [Related]

  • 16. Reduction of dispersion of repolarization and prolongation of postrepolarization refractoriness explain the antiarrhythmic effects of quinidine in a model of short QT syndrome.
    Milberg P, Tegelkamp R, Osada N, Schimpf R, Wolpert C, Breithardt G, Borggrefe M, Eckardt L.
    J Cardiovasc Electrophysiol; 2007 Jun; 18(6):658-64. PubMed ID: 17521304
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Potent inhibition of human cardiac potassium (HERG) channels by the anti-estrogen agent clomiphene-without QT interval prolongation.
    Yuill KH, Borg JJ, Ridley JM, Milnes JT, Witchel HJ, Paul AA, Kozlowski RZ, Hancox JC.
    Biochem Biophys Res Commun; 2004 May 28; 318(2):556-61. PubMed ID: 15120636
    [Abstract] [Full Text] [Related]

  • 19. Pharmacogenetic considerations in diseases of cardiac ion channels.
    Anantharam A, Markowitz SM, Abbott GW.
    J Pharmacol Exp Ther; 2003 Dec 28; 307(3):831-8. PubMed ID: 14561846
    [Abstract] [Full Text] [Related]

  • 20. Beta-blockers as antiarrhythmic agents.
    Zicha S, Tsuji Y, Shiroshita-Takeshita A, Nattel S.
    Handb Exp Pharmacol; 2006 Dec 28; (171):235-66. PubMed ID: 16610347
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.